← Who reports today · Health Care
Amgen (AMGN) earnings date & Q3 2026 results
Net income
$3,864M
up 20.1% y/y
Total revenues
$10,365M
up 8.5% y/y
Operating income
$3,710M
up 46.9% y/y
Next report
~ Feb 2
not announced yet
The quarter in brief
Amgen's Q3 2026 total revenues rose 8% to $10,365 million, and operating income rose 47% to $3,710 million. Net income grew 20% to $3,864 million and diluted EPS rose 19% from $5.93 to $7.08.
Key growth driver: Revenue growth of +9% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report
All figures in $M.
| Line item | Amount and change |
|---|---|
| Product sales | $9,883 · +8.2% |
| Other revenues | $482 · +14.8% |
| Total revenues | $10,365 · +8.5% |
| Cost of sales | $2,788 · −9.5% |
| Research and development | $2,111 · +11.1% |
| Selling, general and administrative | $1,680 · −2.3% |
| Other | $76 · −76.9% |
| Operating income | $3,710 · +46.9% · 35.8% margin |
| Interest expense, net | $653 · −4.7% |
| Other income, net | $1,629 · −21.7% |
| Income before income taxes | $4,686 · +19.5% |
| Provision for income taxes | $822 · +16.6% · 17.5% effective rate |
| Net income | $3,864 · +20.1% · $7.08/sh · 37.3% margin |
Verdict: Amgen's Q3 2026 total revenues rose 8% to $10,365 million, and operating income rose 47% to $3,710 million. Net income grew 20% to $3,864 million and diluted EPS rose 19% from $5.93 to $7.08.
For full-year 2026 Amgen expects total revenues of $38.9–39.7 billion, GAAP EPS of $18.34–19.28 and non-GAAP EPS of $22.90–23.70. It expects capital expenditures of about $2.6 billion and share repurchases not exceeding $3.0 billion, after no repurchases in Q3 2026. The Q3 dividend was $2.52 per share, up 6% year over year. Free cash flow was $3.7 billion versus $4.2 billion a year earlier.
Source and notation
Source: Amgen press release, 8-K EX-99.1 of 11/03/2026 (SEC EDGAR).
Open as an image: Amgen (AMGN), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Amgen (AMGN) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/amgn. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/amgn"><img src="https://whoreportstoday.com/t/amgn/img/amgen-amgn-earnings-sankey.png" alt="Amgen (AMGN) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/amgn">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/amgn/img/amgen-amgn-earnings-sankey.png
<a href="https://whoreportstoday.com/t/amgn">Amgen (AMGN) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Product sales grew 8% to $9,883 million: Repatha rose 37% to $1,085 million and EVENITY 39% to $751 million, while Prolia fell 45% to $632 million and XGEVA 47% to $288 million.
- Other operating expenses were $76 million versus $329 million, including intangible asset impairments of $59 million versus $400 million.
- R&D expenses rose 11% to $2,111 million, while SG&A fell 2% to $1,680 million.
- Other income, net fell to $1,629 million from $2,080 million, with net gains from equity investments of $1,465 million versus $1,963 million.
- The GAAP tax rate was 17.5% versus 18.0%, and net interest expense eased to $653 million from $685 million.
- Diluted share count rose to 546 million from 542 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Robert A. BradwayChairman of the Board, Chief Executive Officer and President [1]
- Thomas J.W. DittrichExecutive Vice President and Chief Financial Officer [1]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Boeingsince 2016Director
- Amgensince 2006
- Chairman of the Boardsince 2013
- Chief Executive Officersince 2012
- Directorsince 2011
- Presidentsince 2010
- Chief Operating Officer2010–2012
- Executive Vice President and Chief Financial Officer2007–2010
- Vice President, Operations Strategy2006
- Morgan Stanley2001–2006Managing Director, head of banking and corporate finance in Europe
Source: SEC EDGAR: DEF 14A proxy statement, 2026-04-07 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 1
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. · Text: Wikipedia, CC BY-SA 4.0, abridged
The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. Market share (US pharma & biotech): ≈5% by TTM revenue.
Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue $38.9–39.7BEPS (GAAP) $18.34–19.28EPS (non-GAAP) $22.90–23.70 | revenue $36.75BEPS (GAAP) $14.23 | revenue +6…8%EPS (GAAP) +29…35% |
Same quarter a year ago (ended December 31, 2025): revenue $9.87B, EPS (GAAP) $2.45
How we calculate
Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +7%).
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Nov 3, 2026); every figure is checked against the release text.
AMGN earnings history: past report dates
| Nov 3, 2026 Tue | 4:05 pmafter market close | Sep 30, 2026 | $10.4B+8% y/y | $7.08+19% y/y |
| Aug 4, 2026 Tue | 4:03 pmafter market close | Jun 30, 2026 | $10.1B+10% y/y | $4.37+65% y/y |
| Apr 30, 2026 Thu | 4:03 pmafter market close | Mar 31, 2026 | $8.6B+6% y/y | $3.34+4% y/y |
| Feb 3, 2026 Tue | 4:03 pmafter market close | Dec 31, 2025 | ≈$9.9B+9% y/y | ≈$2.45+109% y/y |
| Nov 4, 2025 Tue | 4:04 pmafter market close | Sep 30, 2025 | $9.6B+12% y/y | $5.93+14% y/y |
| Aug 5, 2025 Tue | 4:03 pmafter market close | Jun 30, 2025 | $9.2B+9% y/y | $2.65+92% y/y |
| May 1, 2025 Thu | 4:04 pmafter market close | Mar 31, 2025 | $8.1B+9% y/y | $3.20 |
| Feb 4, 2025 Tue | 4:05 pmafter market close | Dec 31, 2024 | ≈$9.1B+11% y/y | ≈$1.17−18% y/y |
| Oct 30, 2024 Wed | 4:06 pmafter market close | Sep 30, 2024 | $8.5B+23% y/y | $5.22+62% y/y |
| Aug 6, 2024 Tue | 4:05 pmafter market close | Jun 30, 2024 | $8.4B+20% y/y | $1.38−46% y/y |
| May 2, 2024 Thu | 4:03 pmafter market close | Mar 31, 2024 | $7.4B+22% y/y | −$0.21 |
| Feb 6, 2024 Tue | 4:20 pmafter market close | Dec 31, 2023 | ≈$8.2B+20% y/y | ≈$1.42−53% y/y |
| Oct 31, 2023 Tue | 7:15 ambefore market open | Sep 30, 2023 | $6.9B+4% y/y | $3.22−19% y/y |
| Aug 3, 2023 Thu | 4:12 pmafter market close | Jun 30, 2023 | $7.0B+6% y/y | $2.57+5% y/y |
| Apr 27, 2023 Thu | 4:11 pmafter market close | Mar 31, 2023 | $6.1B−2% y/y | $5.28+97% y/y |
| Jan 31, 2023 Tue | 4:15 pmafter market close | Dec 31, 2022 | ≈$6.8B−0% y/y | ≈$3.00−10% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Amgen: 15-year financials
| 2025 | 36,751 | 9,080 | 7,711 | 8,100 | 5,124 |
| 2024 | 33,424 | 7,258 | 4,090 | 10,394 | 4,832 |
| 2023 | 28,190 | 7,897 | 6,717 | 7,359 | 4,556 |
| 2022 | 26,323 | 9,566 | 6,552 | 8,785 | 4,196 |
| 2021 | 25,979 | 7,639 | 5,893 | 8,381 | 4,013 |
| 2020 | 25,424 | 9,139 | 7,264 | 9,889 | 3,755 |
| 2019 | 23,362 | 9,674 | 7,842 | 8,532 | 3,509 |
| 2018 | 23,747 | 10,263 | 8,394 | 10,558 | 3,507 |
| 2017 | 22,849 | 9,973 | 1,979 | 10,513 | 3,365 |
| 2016 | 22,991 | 9,794 | 7,722 | 9,616 | 2,998 |
| 2015 | 21,662 | 8,470 | 6,939 | 9,137 | 2,396 |
| 2014 | 20,063 | 6,191 | 5,158 | 8,234 | 1,851 |
| 2013 | 18,676 | 5,867 | 5,081 | 5,598 | 1,415 |
| 2012 | 17,265 | 5,577 | 4,345 | 5,193 | 1,118 |
| 2011 | 15,582 | 4,312 | 3,683 | 4,552 | 500 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Amgen: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 90,586 | 8,658 | 54,604 | 9,129 | 29,057 | 25,489 |
| 2024 | 91,839 | 5,877 | 60,099 | 11,973 | 29,030 | 23,099 |
| 2023 | 97,154 | 6,232 | 64,613 | 10,944 | 30,332 | 18,392 |
| 2022 | 65,121 | 3,661 | 38,945 | 7,629 | 22,186 | 15,687 |
| 2021 | 61,165 | 6,700 | 33,309 | 7,989 | 19,385 | 12,184 |
| 2020 | 62,948 | 9,409 | 32,986 | 6,266 | 21,144 | 11,653 |
| 2019 | 59,707 | 9,673 | 29,903 | 6,037 | 18,440 | 12,835 |
| 2018 | 66,416 | 12,500 | 33,929 | 6,945 | 37,618 | 13,488 |
| 2017 | 79,954 | 25,241 | 35,342 | 3,800 | 49,476 | 9,020 |
| 2016 | 77,626 | 29,875 | 34,596 | 3,241 | 46,010 | 11,204 |
| 2015 | 71,449 | 28,083 | 31,429 | 4,144 | 38,515 | 8,664 |
| 2014 | 69,009 | 25,778 | 30,715 | 3,731 | 34,713 | 7,008 |
| 2013 | 66,125 | 22,096 | 32,128 | 3,805 | 27,367 | 7,947 |
| 2012 | 54,298 | 19,060 | 26,529 | 3,257 | 31,209 | 8,191 |
| 2011 | 48,871 | 19,029 | 21,428 | 6,946 | 27,593 | 5,754 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 10,432 | 8,355 | +2,077 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 3,350 | 4,035 | |
| · incl. stock-based comp (non-cash)share-based compensation | 368 | 369 | |
| Capexpurchases of property & equipment | −1,812 | −1,216 | −596 |
| Free cash flow ≈operating cash flow − capex | 8,620 | 7,139 | +1,481 |
| Investing activities, netcapex, acquisitions, securities | −1,934 | −1,250 | −684 |
| Financing activities, netdebt, buybacks, dividends | −4,437 | −9,633 | +5,196 |
| · incl. dividends paid | −4,083 | −3,841 | −242 |
| Net change in cash | 4,061 | −2,528 | +6,589 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $14.4B (15% of total assets). Compare with other S&P 500 companies →
Corporate governance
1.5/2mostly good
- Oct 2016The court granted final approval of the settlement in In re Amgen Inc. Securities Litigation (a suit over 2004–2007 statements on Aranesp/Epogen; the $95M amount was announced in 07/2016). sec.gov ↗
- Feb 2026The 2025 10-K discloses an unresolved class action, Roofers Local No. 149 (2023), over disclosure of a tax dispute with the IRS. sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Dec 2025Diluted shares −8% over 2020–2025; SBC of $0.49B = 1.3% of revenue; the dividend rose from $6.56 to $9.66 per share. data.sec.gov ↗
Scoring: 2.0 −0.5 (criterion 9: investor suit over Aranesp/Epogen settled for $95M; settlement approved by the court in Oct 2016, within 10 years) = 1.5
- Share classes
- Single class of common stock (2025 10-K cover).
- Dilution
- Diluted shares −8% over 2020–2025, SBC 1.3% of revenue.
- Disclosure
- Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
- Dividends
- Dividend raised every year ($6.56 → $9.66 over 2020–2025); buybacks were nearly absent in 2023–2025 after the all-cash Horizon acquisition — no buyback commitments, no deduction.
- Lawsuits & regulators
- 2007 investor suit (Aranesp/Epogen) settled for $95M, court approval in Oct 2016 — full deduction; the Roofers suit (2023, IRS tax dispute) and derivative suits are unresolved — no deduction.
- Related parties
- The 2026 proxy lists only a senior executive's son-in-law on staff (~$0.37M) — immaterial.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Amgen (AMGN) earnings: FAQ
When is AMGN's next earnings date?
We have not yet seen an announcement of the date from Amgen (AMGN). Based on last year's report on Feb 3, 2026, the next report is expected around Feb 2, 2027.
What time does AMGN report earnings?
Amgen usually reports after market close: its latest results release was filed with the SEC at 4:05 pm ET on Nov 3, 2026.
When did AMGN last report earnings?
Amgen reported Q3 2026 results on Nov 3, 2026.
What has Amgen guided for FY2026?
Company guidance for FY2026: revenue $38.9–39.7B; EPS (GAAP) $18.34–19.28; EPS (non-GAAP) $22.90–23.70. A year ago (FY2025): revenue $36.75B, EPS (GAAP) $14.23. Implied growth: revenue +6…8%, EPS (GAAP) +29…35%. Source: the company's earnings release (Form 8-K filed Nov 3, 2026).
Where can I find Amgen's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to AMGN's filings; this page breaks the latest report down in a Sankey chart.
What was AMGN's net income in Q3 2026?
Amgen reported net income of $3,864M for Q3 2026 (+20.1% year over year), under US GAAP.
Does Amgen pay dividends?
Yes. In 2025, Amgen paid $5,124M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Amgen's revenue changed since 2011?
Per its 10-K filings, revenue grew 2.4x: $15,582M in 2011 and $36,751M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q4 FY2026 · all reports